{"organizations": [], "uuid": "aa92b6197f17182a610df1777f570e2460de25fc", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180518.html", "section_title": "Archive News &amp; Video for Friday, 18 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-rxi-pharmaceuticals-announces-posi/brief-rxi-pharmaceuticals-announces-positive-results-from-phase-2-trial-with-samcyprone-for-treatment-of-common-warts-idUSASC0A2Y2", "country": "US", "domain_rank": 408, "title": "BRIEF-Rxi Pharmaceuticals Announces Positive Results From Phase 2 Trial With Samcyprone For Treatment Of Common Warts", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.698, "site_type": "news", "published": "2018-05-19T00:02:00.000+03:00", "replies_count": 0, "uuid": "aa92b6197f17182a610df1777f570e2460de25fc"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-rxi-pharmaceuticals-announces-posi/brief-rxi-pharmaceuticals-announces-positive-results-from-phase-2-trial-with-samcyprone-for-treatment-of-common-warts-idUSASC0A2Y2", "ord_in_thread": 0, "title": "BRIEF-Rxi Pharmaceuticals Announces Positive Results From Phase 2 Trial With Samcyprone For Treatment Of Common Warts", "locations": [], "entities": {"persons": [{"name": "hase", "sentiment": "none"}], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "rxi pharmaceuticals corp", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 18 (Reuters) - Rxi Pharmaceuticals Corp:\n* RXI PHARMACEUTICALS ANNOUNCES POSITIVE RESULTS FROM PHASE 2 TRIAL WITH SAMCYPRONE™ FOR THE TREATMENT OF COMMON WARTS\n* RXI PHARMACEUTICALS ANNOUNCES POSITIVE RESULTS FROM PHASE 2 TRIAL WITH SAMCYPRONE™ FOR THE TREATMENT OF COMMON WARTS\n* RXI PHARMACEUTICALS CORP - STUDY SUCCESSFULLY MEETS ITS PRIMARY EFFECTIVENESS OBJECTIVES AND ITS SECONDARY SAFETY AND TOLERABILITY OBJECTIVES\n* RXI PHARMACEUTICALS CORP - STUDY RESULTS SHOW THAT SAMCYPRONE WAS SAFE AND WELL TOLERATED Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-19T00:02:00.000+03:00", "crawled": "2018-05-19T15:29:30.075+03:00", "highlightTitle": ""}